Clinical Trials Logo
  1. Home
  2. Alpha 1-Antitrypsin Deficiency
  3. NCT03815396

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency — rhAAT-Fc  

Alpha-1 Antitrypsin Deficiency Clinical Trial

Official title:
An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

Clinical Trial Summary

This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing schedule is IV every 3 to 4 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03815396
Study type Interventional
Source Inhibrx, Inc.
Contact
Status Completed
Phase Phase 1
Start date July 19, 2019
Completion date August 18, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT02547532 - Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00005292 - Alpha1-antitrypsin Deficiency Registry N/A
Withdrawn NCT02900183 - Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Phase 2
Terminated NCT02502201 - Environment Effect on Six-Minute Walk Test Performance N/A
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Recruiting NCT04262284 - Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Recruiting NCT06186492 - A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) Phase 1
Completed NCT01054339 - Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT03008915 - Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT01419158 - Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT00500123 - The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Completed NCT05727800 - A Phase 1, First-in-human Study of VX-668 Phase 1
Active, not recruiting NCT05643495 - A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype Phase 2
Completed NCT02810327 - Alpha-1 Carrier Genomics Study
Terminated NCT02363946 - A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) Phase 1
Completed NCT03804021 - Long-Term Follow-up Study of ADVM-043
Active, not recruiting NCT02014415 - Alpha-1 Antitrypsin Deficiency Adult Liver Study
Terminated NCT01241942 - Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability N/A
Recruiting NCT01851642 - Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs